Evidence for Chronic Kidney Disease-Mineral and Bone Disorder Associated With Metabolic Pathway Changes.
Abnormalities in the levels of calcium, phosphorus, and parathyroid hormone (PTH) in serum are typical for patients with chronic kidney disease (CKD). They are used routinely to predict the onset of CKD-mineral and bone disorder (MBD). However, CKD-MBD associated with metabolic pathway imbalance is not well understood.The objective of the study was to identify endogenous metabolic signatures in patients with intact PTH using mass spectrometry-based metabolomics. This study was a cross-sectional study. Ultra performance liquid chromatography-Quadrupole Time-of-Flight/mass spectrometry-based metabolic profiling was employed to analyze serum samples from 19 disease controls (DCs) (intact parathyroid hormone [iPTH] 150-300 pg/mL) and 19 secondary hyperparathyroidism (SHPT) patients (iPTH >300 pg/mL) (the training data set) to identify metabolic biomarkers for CKD-MBD. Then, another set of samples including 19 DCs (iPTH 150-300 pg/mL) and 19 SHPT patients (iPTH >300 pg/mL) (the test data set) were used to validate the potential biomarkers identified.Metabolic profiling analyses revealed different patterns of endogenous metabolites between the SHPT and the DC groups. A total of 32 unique metabolites were identified and 30 metabolites were elevated in the iPTH compared with control serum pools. Cytidine and L-phenylalanine were downregulated in the SHPT patients. The metabolic signatures identified were assessed respectively by an internal 10-fold cross validation with an accuracy of 91.4% and an external validation with an accuracy of 71.1%, a sensitivity of 73.7%, and a specificity of 68.4%.Mass spectrometry-based metabolomic analyses for SHPT patients promises immense potential for early diagnosis and therapy monitoring. Our results indicated that the onset of CKD-MBD is associated with pathway changes of protein synthesis and metabolism, amino acid metabolism, energy metabolism, and steroid hormone metabolism, with obvious promise for better understanding the pathogenesis of this disease. Several metabolic biomarkers were identified, which warrant further development.
From the School of Pharmacy (QW, ZZ, ZH, XD, ZL, YC); Department of Nephrology (XL, TW, HW, ZG), Changhai Hospital, Second Military Medical University, Shanghai, China; and Proteomics/Mass Spectrometry Facility (QL), Center for Functional Genomics, University at Albany, Rensselaer, NY.
Qiong
Q
Wu
Xueli
X
Lai
Zhenyu
Z
Zhu
Zhanying
Z
Hong
Xin
X
Dong
Tieyun
T
Wang
Haiyan
H
Wang
Ziyang
Z
Lou
Qishan
Q
Lin
Zhiyong
Z
Guo
Yifeng
Y
Chai
D000368:Aged; D000596:Amino Acids / Q000378:metabolism; D015897:Comorbidity; D004734:Energy Metabolism; D005260:Female; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000453:epidemiology / Q000378:metabolism; D008297:Male; D013058:Mass Spectrometry; D008659:Metabolic Diseases / Q000453:epidemiology*; D055432:Metabolomics; D008875:Middle Aged; D051436:Renal Insufficiency, Chronic / Q000453:epidemiology* / Q000378:metabolism*
D000596:Amino Acids